Illumina Q2 Revenues Down 2 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina's second-quarter revenues retreated 2 percent year over year, but beat the consensus Wall Street estimate, the company reported after the close of the market on Tuesday.

For the three months ended July 1, the San Diego firm had revenues of $280.6 million, compared to $287.5 million a year ago, and above analyst estimates of $278.7 million. Product revenues slid to $258.8 million from $269.9 million a year ago, while service and other revenues rose to $21.8 million from $17.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.